Fmr LLC Has $18.68 Million Holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL)

FMR LLC decreased its holdings in Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL - Free Report) by 41.5% in the third quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 5,075,837 shares of the company's stock after selling 3,600,886 shares during the quarter. FMR LLC owned 7.14% of Zentalis Pharmaceuticals worth $18,679,000 as of its most recent filing with the SEC.

Other institutional investors have also made changes to their positions in the company. SG Americas Securities LLC acquired a new position in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $58,000. Values First Advisors Inc. lifted its holdings in Zentalis Pharmaceuticals by 5.4% during the 2nd quarter. Values First Advisors Inc. now owns 74,925 shares of the company's stock worth $306,000 after buying an additional 3,859 shares in the last quarter. Bank of New York Mellon Corp raised its position in shares of Zentalis Pharmaceuticals by 15.1% during the second quarter. Bank of New York Mellon Corp now owns 333,719 shares of the company's stock worth $1,365,000 after acquiring an additional 43,839 shares during the last quarter. Anfield Capital Management LLC bought a new position in Zentalis Pharmaceuticals in the second quarter valued at about $40,000. Finally, Rhumbline Advisers increased its position in Zentalis Pharmaceuticals by 13.8% in the second quarter. Rhumbline Advisers now owns 94,213 shares of the company's stock worth $385,000 after purchasing an additional 11,451 shares during the period.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on the stock. Oppenheimer reiterated an "outperform" rating and set a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Monday, September 16th. Guggenheim dropped their target price on shares of Zentalis Pharmaceuticals from $12.00 to $8.00 and set a "buy" rating for the company in a research report on Friday, November 15th. Finally, HC Wainwright restated a "buy" rating and issued a $20.00 price target on shares of Zentalis Pharmaceuticals in a research report on Friday, November 15th. Five research analysts have rated the stock with a hold rating and four have issued a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Hold" and a consensus price target of $10.00.

Zentalis Pharmaceuticals Trading Down 3.0 %

Shares of Zentalis Pharmaceuticals stock traded down $0.11 during trading hours on Wednesday, reaching $3.50. 761,617 shares of the company's stock were exchanged, compared to its average volume of 1,303,972. The company has a 50 day moving average of $3.33 and a two-hundred day moving average of $4.37. The stock has a market cap of $249.41 million, a P/E ratio of -1.45 and a beta of 1.83. Zentalis Pharmaceuticals, Inc. has a fifty-two week low of $2.66 and a fifty-two week high of $18.07.

Zentalis Pharmaceuticals (NASDAQ:ZNTL - Get Free Report) last issued its earnings results on Tuesday, November 12th. The company reported ($0.56) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.92) by $0.36. As a group, analysts expect that Zentalis Pharmaceuticals, Inc. will post -2.48 earnings per share for the current fiscal year.

About Zentalis Pharmaceuticals

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.